Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-13
2008-05-13
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S161000, C514S165000
Reexamination Certificate
active
10600266
ABSTRACT:
A combination of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, which possess excellent inhibitory activity against platelet aggregation and thrombogenesis, and is useful for preventing or treating diseases caused by thrombus or embolus.
REFERENCES:
patent: 4080447 (1978-03-01), Amselem
patent: 4537894 (1985-08-01), Blanchard et al.
patent: 5288726 (1994-02-01), Koike et al.
patent: 5401730 (1995-03-01), Sauvage et al.
patent: 5989578 (1999-11-01), Bernat et al.
patent: 6248729 (2001-06-01), Coniglio et al.
patent: 6509348 (2003-01-01), Ogletree
patent: 6642252 (2003-11-01), Bisacchi et al.
patent: 6670386 (2003-12-01), Sun et al.
patent: 6706720 (2004-03-01), Atwal et al.
patent: 0 542 411 (1993-05-01), None
patent: 1 298 132 (2003-04-01), None
patent: 6-41139 (1994-02-01), None
patent: 2000-205396 (2000-07-01), None
patent: 2000-266780 (2000-09-01), None
patent: 2002-145883 (2002-05-01), None
patent: WO 97/29753 (1997-08-01), None
Sugidachi et al., “The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antogonist properties”,British Journal of Pharmacology, 2000, vol. 209, No. 7, pp. 1439 to 1446.
Database CA on STN, AN.133:187474, ASAI, Fumitoshi et al., CS-747, a new platelet ADP receptor antagonist Annual Report of Sankyo Research Laboratories, 1999, vol. 51, pp. 1 to 44, abstract.
Saniabadi AR et al., “Effect of dipyridamole alone and in combination with aspirin on whole blood platelet aggregation, PGI2 generation, and red cell deformability ex vivo in man”,Cardiovascular Research, 1991, vol. 25, No. 3, pp. 177 to 183.
J. Cardiovasc. Pharmacol., vol. 49, No. 3, Mar. 2007, p. 167-173.
Seminars in Thrombosis and Hemostasis, vol. 31, No. 2, 2005, p. 184-194.
Asai Fumitoshi
Inoue Teruhiko
Ogawa Taketoshi
Sugidachi Atsuhiro
Frishauf Holtz Goodman & Chick P.C.
Kwon Brian
Sankyo Company Limited
Ube Industries Ltd.
LandOfFree
Medicinal compositions containing aspirin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicinal compositions containing aspirin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicinal compositions containing aspirin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3949222